Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Pain 4 Breakthrough Cancer Pain 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Waldenstrom Macroglobulinemia 1 Uterine Cervical Neoplasms 1 Thrombocythemia, Essential 1 Sezary Syndrome 1 Sarcoma 1 Quality of Life 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Postoperative Complications 1 Polycythemia Vera 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Ovarian Neoplasms 1 Neuralgia 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Mycosis Fungoides 1 Multiple Myeloma 1 Monoclonal Gammopathy of Undetermined Significance 1 Lymphoproliferative Disorders 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Surveys and Questionnaires 1 Quality of Life 1 Fentanyl 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Quality of Life × Fentanyl × Clear all

NCT01936636 2015-11-05

RELIEF

Galena Biopharma, Inc.

Quality of Life

Data powered by HemOnc (CC BY 4.0) Colophon ⚡